Researchers sought to determine whether combining melflufen with dexamethasone would be safe and effective in patients with relapsed/refractory multiple myeloma with extramedullary disease.
Researchers sought to determine whether therapy with carfilzomib, lenalidomide, and dexamethasone would be effective for patients with newly diagnosed multiple myeloma.
Patients with active multiple myeloma may have insufficient responses to mRNA COVID-19 vaccines.
The median duration of response was 35.7 weeks with iberdomide, bortezomib, and dexamethasone compared with not reached in patients who received iberdomide, daratumumab, and dexamethasone or iberdomide, bortezomib, and carfilzomib
The median progression-free survival was not reached in the D-Rd group compared with 34.4 months in the Rd group.
Multiple myeloma is an uncommon form of cancer, and one that may not produce symptoms right away. Because of this, patients with higher risk due to family history, exposure, or other reasons may need more education about it. How can you explain multiple myeloma to your patients?
